drugset
drugset / Trial / NCT04111523

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

NCT04111523 ↗

Phase 1 Completed 78 enrolled Suzhou Yabao Pharmaceutical R&D Co., Ltd.
RandomizedFactorialQuadruple-blindTreatment

Summary

This study is a single-dose incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.

Timeline

Start
2019-03-05
Primary completion
2020-05-26
Completion
2020-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject SY-007 Unknown 1 mg Intravenous
Subject SY-007 Unknown 4 mg Intravenous
Subject SY-007 Unknown 10 mg Intravenous
Subject SY-007 Unknown 20 mg Intravenous
Subject SY-007 Unknown 30 mg Intravenous
Subject SY-007 Unknown 45 mg Intravenous

Indications

stroke disorder